Patents
Literature
4 results about "Cellulose acetate phthalate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cellulose acetate phthalate (CAP), also known as cellacefate (INN) and cellulosi acetas phthalas, is a commonly used polymer phthalate in the formulation of pharmaceuticals, such as the enteric coating of tablets or capsules and for controlled release formulations. It is a cellulose polymer where about half of the hydroxyls are esterified with acetyls, a quarter are esterified with one or two carboxyls of a phthalic acid, and the remainder are unchanged. It is a hygroscopic white to off-white free-flowing powder, granules, or flakes. It is tasteless and odorless, though may have a weak odor of acetic acid. Its main use in pharmaceutics is with enteric formulations. It can be used together with other coating agents, e.g. ethyl cellulose. Cellulose acetate phthalate is commonly plasticized with diethyl phthalate, a hydrophobic compound, or triethyl citrate, a hydrophilic compound; other compatible plasticizers are various phthalates, triacetin, dibutyl tartrate, glycerol, propylene glycol, tripropionin, triacetin citrate, acetylated monoglycerides, etc.
Solid dispersion, preparation method, and pharmaceutical composition thereof
The present invention provides a solid dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof and a carrier. The carrier material includes polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methylcellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethylcellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.
Owner:ANXO PHARMA CO LTD
System for the manufacture of a Pulsincap dosage form containing lovastatin and colesevelam for the treatment of hypercholesterolemia
A system for manufacturing a Pulsincap dosage form containing lovastatin and colesevelam for the treatment of hypercholesterolemia, comprising: a) a fungal cultivation facility configured to cultivate mangrove-associated marine fungi from the group consisting of Aspergillus sp., Penicillium sp., Rhizophus sp. and Fusarium sp. in production media to produce the metabolite lovastatin; b) a microsphere preparation plant for the production of floating lovastatin microspheres using ionotropic gelation technology with chitosan, sodium alginate and calcium carbonate; c) a granulation plant for the production of colesevelam granules using explosives from the group consisting of croscarmellose and microcrystalline cellulose; d) a capsule coating unit configured to coat the capsule body with cellulose acetate phthalate (CAP); and e) a stopper preparation unit configured to prepare hydrogel stoppers and coat them with ethylcellulose.
Owner:AMEEN MANHA ROCKVILLE +9
Budesonide enteric capsule and preparation method thereof
PendingCN121313605AHydroxy compound active ingredientsDigestive systemCelluloseSustained release pellets
The invention provides a budesonide enteric capsule, which is characterized in that resveratrol is used as a pellet core, budesonide, zein, hydroxypropyl methylcellulose acetate succinate, polyvinylpyrrolidone, acetyl triethyl citrate and tween-80 are used for preparing a budesonide sustained-release pellet, and the budesonide enteric capsule is prepared from the budesonide, the zein, the hydroxypropyl methylcellulose acetate succinate, the polyvinylpyrrolidone, the acetyl triethyl citrate and the tween-80. Cellulose acetate phthalate and zinc pectin are adopted to prepare the budesonide enteric-coated sustained-release pellet, and the budesonide enteric-coated capsule prepared through filling has the enteric-coated characteristic, and the effect is better than that of single use of cellulose acetate phthalate or zinc pectin as an enteric-coated material; and the budesonide enteric capsule prepared by taking resveratrol as the pellet core has better ulcerative colitis treatment effect than the budesonide enteric capsule prepared by taking cane sugar as the pellet core.
Owner:CHANGZHOU NO 4 PHARMA FACTORY +1
Solid dispersions, methods of preparation, and pharmaceutical compositions thereof
Some embodiments of the present disclosure provide solid dispersions comprising lurasidone, or a pharmaceutically acceptable salt thereof, and a carrier. The carrier is prepared from the following materials: polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silicon oxide, hydroxypropyl methyl cellulose (HPMC), a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer, acrylic resin, hydroxypropyl cellulose (HPC), polyvinylpyrrolidone, copovidone and ethyl cellulose; the composition may be selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, hydroxypropyl methyl cellulose succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), or a combination thereof.
Owner:ANXO PHARMA CO LTD